Galvanizing bioelectronics

With disease biology expertise from GlaxoSmithKline plc and device development know-how from Verily Life Sciences LLC, newco Galvani Bioelectronics Ltd. plans to bring a commercial-grade bioelectronic therapeutic device to the clinic in about four years.

GSK and Verily formed Galvani last week. Each side will contribute IP, and together will provide up to £540 million ($713.9 million) in funding over seven years. GSK will own 55% of Galvani and Verily, formerly Google Life Sciences, will own the balance. ...